These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 38942618)
1. Metabolic and cardiovascular risks of hormone treatment for transgender individuals. de Silva NL; Dimakopoulou A; Quinton O; Jayasena CN Best Pract Res Clin Endocrinol Metab; 2024 Sep; 38(5):101907. PubMed ID: 38942618 [TBL] [Abstract][Full Text] [Related]
2. Does Gender-Affirming Hormonal Treatment Affect 30-Year Cardiovascular Risk in Transgender Persons? A Two-Year Prospective European Study (ENIGI). Cocchetti C; Castellini G; Iacuaniello D; Romani A; Maggi M; Vignozzi L; Schreiner T; den Heijer M; T'Sjoen G; Fisher AD J Sex Med; 2021 Apr; 18(4):821-829. PubMed ID: 33745831 [TBL] [Abstract][Full Text] [Related]
3. Gender-affirming hormone therapy and cardiovascular health in transgender adults. Ong C; Monita M; Liu M Climacteric; 2024 Jun; 27(3):227-235. PubMed ID: 38597210 [TBL] [Abstract][Full Text] [Related]
4. Safety and rapid efficacy of guideline-based gender-affirming hormone therapy: an analysis of 388 individuals diagnosed with gender dysphoria. Meyer G; Mayer M; Mondorf A; Flügel AK; Herrmann E; Bojunga J Eur J Endocrinol; 2020 Feb; 182(2):149-156. PubMed ID: 31751300 [TBL] [Abstract][Full Text] [Related]
5. Sperm quality in transgender women before or after gender affirming hormone therapy-A prospective cohort study. Rodriguez-Wallberg KA; Häljestig J; Arver S; Johansson ALV; Lundberg FE Andrology; 2021 Nov; 9(6):1773-1780. PubMed ID: 33683832 [TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Risk Associated With Gender Affirming Hormone Therapy in Transgender Population. Aranda G; Halperin I; Gomez-Gil E; Hanzu FA; Seguí N; Guillamon A; Mora M Front Endocrinol (Lausanne); 2021; 12():718200. PubMed ID: 34659112 [TBL] [Abstract][Full Text] [Related]
8. The implications of hormone treatment for cancer risk, screening and treatment in transgender individuals. Berner AM; Atkinson SE Best Pract Res Clin Endocrinol Metab; 2024 Sep; 38(5):101909. PubMed ID: 38964988 [TBL] [Abstract][Full Text] [Related]
10. Effects of gender affirming hormone treatment in transgender individuals - a retrospective cohort study. Muir CA; Guttman-Jones M; Man EJ Endocrine; 2024 Jul; 85(1):370-379. PubMed ID: 38386168 [TBL] [Abstract][Full Text] [Related]
11. Effect of gender-affirming hormone use on coagulation profiles in transmen and transwomen. Scheres LJJ; Selier NLD; Nota NM; van Diemen JJK; Cannegieter SC; den Heijer M J Thromb Haemost; 2021 Apr; 19(4):1029-1037. PubMed ID: 33527671 [TBL] [Abstract][Full Text] [Related]
18. Cardiometabolic Effects of Testosterone in Transmen and Estrogen Plus Cyproterone Acetate in Transwomen. van Velzen DM; Paldino A; Klaver M; Nota NM; Defreyne J; Hovingh GK; Thijs A; Simsek S; T'Sjoen G; den Heijer M J Clin Endocrinol Metab; 2019 Jun; 104(6):1937-1947. PubMed ID: 30602016 [TBL] [Abstract][Full Text] [Related]
19. Effects of gender-affirming hormone therapy on body fat: a retrospective case‒control study in Chinese transwomen. Pei Q; Song Y; Huang Z; Yu H; Xu H; Ye X; Gao L; Gong J; Tian X Lipids Health Dis; 2024 May; 23(1):146. PubMed ID: 38760846 [TBL] [Abstract][Full Text] [Related]
20. Cardiovascular implications of gender-affirming hormone treatment in the transgender population. Dutra E; Lee J; Torbati T; Garcia M; Merz CNB; Shufelt C Maturitas; 2019 Nov; 129():45-49. PubMed ID: 31547912 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]